Outstanding warrants to purchase common stock consisted of the following at June 30, 2026:



Issuance date	Contractual term	Balance sheet classification	Shares of common stock issuable upon exercise of warrant	Weighted average exercise price
	(in years)
July 24, 2017	10	Equity	10,026	$	298.96
April 12, 2018	10	Equity	30,000	$	1.00
July 14, 2021 *	10	Equity	346,077	$	3.99
August 8, 2025	10	Equity	179,104	$	3.35
May 20, 2026 Pre-funded	†	Equity	1,463,000	$	0.01
May 20, 2026 Series A	1	Equity	5,044,000	$	1.96
May 20, 2026 Series B	5	Equity	5,044,000	$	2.34
May 29, 2026 Series A	1	Equity	71,607	$	1.96
May 29, 2026 Series B	5	Equity	71,607	$	2.34
			12,259,421
† such rights shall not expire

Outstanding warrants to purchase common stock consisted of the following at December 31, 2025:



Issuance date	Contractual term	Balance sheet classification	Shares of common stock issuable upon exercise of warrant	Weighted average exercise price
	(in years)
July 24, 2017	10	Equity	15,035	$	298.96
April 12, 2018	10	Equity	30,000	$	1.00
July 14, 2021 *	10	Equity	975,109	$	1.46
August 8, 2025	10	Equity	179,104	$	3.35
			1,199,248

*In connection with the Company’s IPO, preferred stock warrants were automatically converted to Class A common stock warrants. The contractual term of the converted Class A common stock warrants remained consistent with the original term of the preferred stock warrants, with original issue dates between 2017-2020.